Abstract 6 Aim. GO is a potent antibody-directed chemotherapy against CD33 antigen. Two
MRC and SWOG Phase 3 studies have compared standard CT alone or combined with one …

The prognosis of acute myeloid leukemia (AML) in older adults is generally poor. Standard
cytotoxic chemotherapy is usually poorly tolerated and provides dismal results in this patient …

The treatment of older patients with acute myeloid leukaemia, who are not considered
suitable for conventional intensive therapy, is unsatisfactory. Low-dose Ara-C (LDAC) has …

Gemtuzumab ozogamicin (fGO), a humanized anti‐CD33 monoclonal antibody linked to
calicheamicin in combination with intensive chemotherapy gives high response rates in …

Purpose There has been little survival improvement in older patients with acute myeloid
leukemia (AML) in the last two decades. Improving induction treatment may improve the rate …

Background Chemotherapy for elderly patients with acute myeloid leukemia (AML) results in
a median overall survival (OS) of≤ 1 year. Elderly patients often present with cardiac …

This trial tested the safety and efficacy of a regimen consisting of hydroxyurea followed by
azacitidine, 75 mg/m2 for 7 days, and gemtuzumab ozogamicin, 3 mg/m2 on day 8, in older …

Gemtuzumab ozogamicin was recently approved in the United States for the treatment of
older patients with CD33-positive acute myeloid leukemia (AML) in first relapse. However …

We analyzed the safety and efficacy of gemtuzumab ozogamicin (GO) combined with
cytarabine and mitoxantrone in the treatment of 21 patients with acute myeloid leukemia (11 …

This study compared two schedules of low‐dose gemtuzumab ozogamicin (GO) as induction
monotherapy for untreated acute myeloid leukaemia in older patients unfit for intensive …